ReportsnReports adds a new search report "Flow Cytometry 2012: Market Needs, Emerging Developments and Future Use" to its store.

1. 2012 Flow Cytometry Market Needs,
Emerging Developments and Future Use
Report Details:
Published: September 2012
Price: Single User License: US$2355 Corporate User License: US$4710
Biopharm Reports has carried out a study of market needs in the flow cytometry field. This study
examined current techniques and applications, end-users’ plans for using flow cytometry over the next
three years, as well as preferred products, purchasing and new developments. The findings of this study
provide valuable support to developers and vendors operating in this field.
This study involved the participation of 260 experienced flow cytometry users and decision-makers in 53
countries. It investigated current and future applications, current and future purchasing plans, research
vs. clinical use across the study, new and emerging applications, end-users’ principal flow cytometers and
their strengths and weaknesses, current annual and future budgets, budget breakdown, main
consumables, challenges, innovation, use of analysis (offline) software, quality control guidelines, sample
preparation, and other areas. As part of this study, end-users provided details of their anticipated
purchases from suppliers in this field, over the period 2012 – 2015.
http://www.reportsnreports.com/reports/191887-
Buy your copy of this report @
flow-cytometry-2012-market-needs-emerging-developments-and-future-
use.html
Key Findings
 Routine use: Use of flow cytometry (FC) by end-users for routine (developed and validated) FC
tests, the development or validation of FC tests and for qualitative discovery using FC methods.
 Companies: End-users' purchases/use of FC systems from more than 25 companies and their
anticipated use of these systems over the next three years, each ranked according to their
competitive position
 General and clinical: FC use (defined in this study description) by research scientists/research
managers and clinicians/physicians
 FC methods: Current use of more than 25 FC general applications and 15 clinical applications by
end-users and the anticipated use of these applications over the next three years, each ranked
according to their competitive position.

2.  Main applications: End-users’ two main applications of FC, each ranked according to their
competitive position.
 New applications: New FC applications used by end-users in the last three years, each ranked
according to their competitive position.
 Emerging applications: Emerging applications of FC, indicated by end-users.
 Main flow cytometer: End-users’ main flow cytometer, each ranked according to their competitive
position.
 Strengths: End-users’ disclosures of the strengths of their main flow cytometer, each ranked
according to their competitive position.
 Weaknesses: End-users’ disclosures of the weaknesses of their main flow cytometer, each
ranked according to their competitive position.
 Current financial budgets: End-users’ annual financial budgets for FC studies.
 Current budget breakdown: The breakdown of end-users’ FC financial budgets in nine key areas,
relating to their current expenditure on FC products and activities.
 Future financial budgets: End-users’ anticipated financial budget changes (percentage increases
or decrease, a measure of the financial growth of this field) over the next three years, relating to
their FC activities.
 Consumables: End-users’ top consumables, associated with their FC activities.
 Quality control guidelines: End-users’ adherence to quality control guidelines or procedures,
relating to the conduct of FC studies.
 Cost per sample: End-users’ disclosures on the costs per sample analysed, using FC.
 Current challenges: End-users’ disclosures on the parameters or measurements that present the
greatest technical challenges to FC analysis, together with the associated sample types
(matrices), associated FC methods and underlying reasons.
 Innovation: End-users’ disclosures relating to 11 key areas of required innovation in the FC field,
each ranked (on a scale of 1 to 10) according to their importance.
 Biomarkers: End-users’ application of FC methods for the study of disease biomarkers, namely
molecular types and their clinical utilities.
 Organisations: End-users organisations include clinics or hospitals, government bodies, large
international companies, research institutes, small and medium sized companies, universities and
veterinary centres.
 Fields: End-users professional fields include biotechnology, chemicals, clinical or hospital,
defence, energy, environmental, food and drink, forensics, geology, government, healthcare,
natural products, pharmaceuticals, research institutes, security and universities.
 Therapeutic areas: End-users’ FC activities in terms of their general therapeutic area (20 different
areas covered), including the main diseases to which their work in this field relates.

3.  Software: End-users’ disclosures on their preferred analysis (off-line) software, associated with
FC studies.
 Purpose: End-users’ underlying reasons for using FC analysis across 17 major fields
(biotechnology, chemicals, clinical or hospital, defence, diagnostics (medical), energy,
environmental, food and drink, forensics, geology, government, healthcare, natural products,
pharmaceuticals, research institutes, security, university), each ranked according to their relative
importance.
 Study samples: Study sample types analysed by end-users using FC methods, each ranked
according to their relative importance.
 Sample preparation: The use of sample preparation methods by end-users for FC studies, each
ranked according to their importance.
Explore reports related to Biotechnology Market @ http://www.reportsnreports.com/market-
research/biotechnology/
Contact:
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
+ 1 888 391 5441
sales@reportsandreports.com
Connect With Us: